Results 181 to 190 of about 47,221 (287)

Long-term Subclinical Cardiotoxicity of Modern Cardiotoxic Treatment Protocols in Childhood Cancer Survivors Assessed by Cardiovascular Magnetic Resonance T1 Mapping and Circulatory Biomarkers. [PDF]

Cardiovasc Toxicol
Panovský R, Tomandlová M, Mojica-Pisciotti ML, Kepák T, Máchal J, Feitová V, Frič J, Hortová-Kohoutková M, Holeček T, Tomandl J, Opatřil L, Kincl V.   +11 more
europepmc   +1 more source

Childhood cancer: late effects of cancer treatment [PDF]

, 2007
Vandecruys, Els
core   +1 more source

The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B‐Cell Lymphoma (CLSG‐CNS‐01): A Randomized, Multicenter, Prospective Phase 3 Trial

Hematological Oncology, Volume 44, Issue 3, May 2026.
ABSTRACT The randomized, multicenter, prospective Phase 3 trial (NCT02777736) evaluated central nervous system (CNS) prophylaxis using either intravenous (i.v.) or intrathecal (i.t.) methotrexate (MTX) in diffuse large B‐cell lymphoma (DLBCL). Treatment consisted of six cycles of R‐CHOP + 2xR or DA‐EPOCH‐R + 2xR. Patients with intermediate or high‐risk
H. Mocikova, L. Gaherova, T. Jancarkova, A. Suri, A. Janikova, K. Steinerova, D. Belada, R. Pytlik, J. Duras, M. Trnkova, P. Blahovcova, T. Kozak, M. Trneny   +12 more
wiley   +1 more source

Protecting the Heart Against Anthracyclines: The Elusive Search for the Optimal Cardiomyocyte Model. [PDF]

JACC Basic Transl Sci
Narvaez-Paliza JM, Asnani A.
europepmc   +1 more source

Carbohydrate‐Based Drug Discovery: Synthetic Strategies and Clinical Applications

Israel Journal of Chemistry, Volume 66, Issue 3, May 2026.
The picture depicts the molecules discussed in the review. On the left side, the general scaffold of sugars is shown. Next to it are four carbohydrate‐based molecules, including remdesivir, islatravir, empagliflozin, and Globo‐H. Remdesivir and islatravir contain a substituted ribose ring attached to a modified nucleobase.
Stephan Scheeff, Jemma Arakelyan, Billy Wai‐Lung Ng   +2 more
wiley   +1 more source

The trajectory of fatigue over time in breast cancer patients treated with chemotherapy: exploring the effect of anthracycline-based chemotherapy. [PDF]

Breast
Kastelein A, Kervezee L, Mink van der Molen DR, Evers DJ, van der Pol CC, Doeksen A, Chavannes NH, Gelderblom H, Neefjes J, Verkooijen HM, May AM.   +10 more
europepmc   +1 more source

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Systematic Review of Breast and Node Pathologic Response

Journal of Surgical Oncology, Volume 133, Issue 6, Page 712-719, May 2026.
ABSTRACT Introduction Pathological complete response (pCR) after neoadjuvant chemotherapy is associated with improved prognosis in patients with triple‐negative breast cancer (TNBC). Differences in pathological response rates between the breast and axillary lymph nodes have prompted interest in understanding response patterns that may, in the future ...
Milena Martello Cristófalo, Jonathan Yugo Maesaka, Deise Azevedo Pereira, Gabriela Bezerra Nóbrega, Yedda Nunes Reis, José Maria Soares Júnior, Edmund Chada Baracat, José Roberto Filassi   +7 more
wiley   +1 more source

Association of early dexrazoxane with reduced cardiotoxicity risk in sarcoma patients treated with anthracycline chemotherapy. [PDF]

Oncologist
Jang KH, Wallins JS, Lin IH, Movva S, Tap WD, Liu JE, Yu AF.   +6 more
europepmc   +1 more source

MiR‐145‐5p Attenuates Doxorubicin‐Induced Heart Injury Through Targeting Cardiomyocyte Pyroptosis

The Kaohsiung Journal of Medical Sciences, Volume 42, Issue 5, May 2026.
ABSTRACT Doxorubicin (DOX), a potent anthracycline chemotherapeutic, exhibits dose‐dependent cardiotoxicity that limits its clinical utility. Although miR‐145‐5p demonstrates cardioprotective properties in cardiovascular diseases, its role in DOX‐induced cardiomyopathy remains undefined.
Xing‐Tao Chen, Yong‐Hong Yu, Yan‐Hua Du, Lin Xu, Xiang‐Ping Meng   +4 more
wiley   +1 more source

Caught in the crossfire: cardiac complications of cancer therapy. [PDF]

J Clin Invest
Guerra G, Mergiotti M, Ardehali H, Hirsch E, Ghigo A.   +4 more
europepmc   +1 more source